Clinical trial
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate…
NCT00090363 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00090363 |
|---|---|
| Title | ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) |
| Official title | Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | ZD4054 15 mg, Placebo, ZD4054 10 mg |
| Enrollment | 447 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2008 |
| Completion | Aug 1, 2011 |
| First posted | Aug 30, 2004 |
| Last update posted | Jan 8, 2013 |
| Countries | Australia, Belgium, Canada, Denmark, Finland, France, Indonesia, Netherlands, Norway, Poland, Sweden, Switzerland and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: